Arabic Arabic English English French French German German
dark

IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA

IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the ATR inhibitor of IMPACT Therapeutics, representing a major leap of the company’s global development strategy for its synthetic lethality pipelines. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Two new cases in Northland, reports of possible positive results in Tongan returnee

Next Post

Interim report January – September 2021: Profitable growth and Igenomix acquisition

Related Posts
Total
0
Share